Related Experiment Video

Updated: Mar 14, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

14.0K

Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets,

Lucas L van den Hoogen1,2, Ruth D E Fritsch-Stork2,3,4, Marjan A Versnel5

  • 1Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.

Annals of the Rheumatic Diseases
|October 1, 2016
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Antiphospholipid SyndromeAutoimmune DiseasesCytokinesInflammationSystemic Lupus Erythematosus

More Related Videos

On-Chip Endothelial Inflammatory Phenotyping
12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

11.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

14.0K
On-Chip Endothelial Inflammatory Phenotyping
12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

11.4K

Related Concept Videos

Inflammation01:38

Inflammation

63.6K
Overview
63.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
T Cell Types and Functions01:24

T Cell Types and Functions

3.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K

Articles linked to this work by shared authors, journal, and citation graph.

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease.

Frontiers in immunology·2026

Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial.

The Lancet. Rheumatology·2026

Proteomic Signatures Over Age Reveal Significant Changes From Infancy Till Late Adulthood.

Advanced biology·2026

Exaggerated IFN-I Response in Long COVID PBMCs Following Exposure to Viral Mimics.

Journal of clinical immunology·2025

Proteins linked to type II interferon response in Sjögren's disease: novel indicators for disease monitoring and predicting treatment response to leflunomide and hydroxychloroquine combination therapy.

Frontiers in immunology·2025

Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis.

iScience·2025

The ASAS core set for the assessment of axial spondyloarthritis in clinical practice.

Annals of the rheumatic diseases·2026

Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis.

Annals of the rheumatic diseases·2026

Multiomics landscape of systemic sclerosis: from autoantibody-positivity to established disease.

Annals of the rheumatic diseases·2026

IgG4-related disease is not associated with an increased incidence of malignancy in a large, single-centre cohort.

Annals of the rheumatic diseases·2026

Early arthritis signs and symptoms revisited-is synovitis what we are assessing?

Annals of the rheumatic diseases·2026

Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review.

Annals of the rheumatic diseases·2026

Phenotypic shift from active class IV lupus nephritis to lupus podocytopathy: a case report highlighting the treatment-altering role of repeat kidney biopsy.

Frontiers in immunology·2026

Investigating the association between interferons and flares of systemic lupus erythematosus at a single cell level.

Frontiers in immunology·2026

Case Report: Acute liver failure in systemic lupus erythematosus with autoimmune hepatitis-primary biliary cholangitis overlap: a belimumab-containing regimen and longitudinal follow-up.

Frontiers in immunology·2026

Symptomatic Superior Vena Cava Lipoma Causing Near-Complete Venous Obstruction: A Case Report and Literature Review.

Vascular and endovascular surgery·2026

Refractory hypoparathyroidism in paediatric autoimmune polyglandular syndrome type 1: successful long-term use of teriparatide.

Pediatric endocrinology, diabetes, and metabolism·2026

S. carcinoma arising in a breast implant: a case report and review of the literature.

Journal of medical case reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us